Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMorote Robles, Joan
dc.contributor.authorBorque Fernando, Ángel
dc.contributor.authorTriquell Llauradó, Marina
dc.contributor.authorCelma Domènech, Ana
dc.contributor.authorRegis Plácido, Lucas
dc.contributor.authorEscobar Amores, Manuel
dc.contributor.authorMast, Richard
dc.contributor.authorTorres Ramirez, Inés de
dc.contributor.authorSemidey Raven, Maria Eugenia
dc.contributor.authorSantamaria Margalef, Anna
dc.contributor.authorPlanas Morin, Jacques
dc.contributor.authorTrilla Herrera, Enric
dc.date.accessioned2022-08-11T11:19:50Z
dc.date.available2022-08-11T11:19:50Z
dc.date.issued2022-03-21
dc.identifier.citationMorote J, Borque-Fernando A, Triquell M, Celma A, Regis L, Escobar M, et al. The Barcelona Predictive Model of Clinically Significant Prostate Cancer. Cancers. 2022 Mar 21;14(6):1589.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/7990
dc.descriptionClinically significant prostate cancer; Magnetic resonance imaging; Predictive model
dc.description.abstractA new and externally validated MRI-PM for csPCa was developed in the metropolitan area of Barcelona, and a web-RC designed with the new option of selecting the csPCa probability threshold. The development cohort comprised 1486 men scheduled to undergo a 3-tesla multiparametric MRI (mpMRI) and guided and/or systematic biopsies in one academic institution of Barcelona. The external validation cohort comprised 946 men in whom the same diagnostic approach was carried out as in the development cohort, in two other academic institutions of the same metropolitan area. CsPCa was detected in 36.9% of men in the development cohort and 40.8% in the external validation cohort (p = 0.054). The area under the curve of mpMRI increased from 0.842 to 0.897 in the developed MRI-PM (p < 0.001), and from 0.743 to 0.858 in the external validation cohort (p < 0.001). A selected 15% threshold avoided 40.1% of prostate biopsies and missed 5.4% of the 36.9% csPCa detected in the development cohort. In men with PI-RADS <3, 4.3% would be biopsied and 32.3% of all existing 4.2% of csPCa would be detected. In men with PI-RADS 3, 62% of prostate biopsies would be avoided and 28% of all existing 12.4% of csPCa would be undetected. In men with PI-RADS 4, 4% of prostate biopsies would be avoided and 0.6% of all existing 43.1% of csPCa would be undetected. In men with PI-RADS 5, 0.6% of prostate biopsies would be avoided and none of the existing 42.0% of csPCa would be undetected. The Barcelona MRI-PM presented good performance on the overall population; however, its clinical usefulness varied regarding the PI-RADS category. The selection of csPCa probability thresholds in the designed RC may facilitate external validation and outperformance of MRI-PMs in specific PI-RADS categories.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;14(6)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPròstata - Càncer - Prognosi
dc.subjectPròstata - Càncer - Imatgeria per ressonància magnètica
dc.subject.meshProstatic Neoplasms
dc.subject.mesh/diagnostic imaging
dc.subject.meshMagnetic Resonance Imaging
dc.titleThe Barcelona Predictive Model of Clinically Significant Prostate Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers14061589
dc.subject.decsneoplasias de la próstata
dc.subject.decs/diagnóstico por imagen
dc.subject.decsimagen por resonancia magnética
dc.relation.publishversionhttps://doi.org/10.3390/cancers14061589
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Morote J, Triquell M, Celma A, Regis L, Trilla E] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Borque-Fernando A] Department of Urology, Hospital Universitario Miguel Servet, IIS-Aragon, Zaragoza, Spain. [Escobar M, Mast R] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [de Torres IM, Semidey ME] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Ciències Morfològiques, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Santamaría A] Grup de Recerca en Urologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Planas J] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid35326740
dc.identifier.wos000775851700001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01666
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record